Why Is Fisher & Paykel Healthcare (ASX:FPH) Selling Land in Drury to Health New Zealand?

Sonal Goyal

05 November 2026 06:16 PM AEDT

Why Is Fisher & Paykel Healthcare (ASX:FPH) Selling Land in Drury to Health New Zealand?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

• Fisher & Paykel Healthcare has agreed to sell 13 hectares of its 105-hectare Karaka Road site in Drury to Health New Zealand for NZ$45.3 million.

• Health NZ intends to use the land for a future hospital Facility to serve South Auckland's growing population.

• Fisher & Paykel Healthcare retains the remaining land for its planned second New Zealand campus, with a rezoning application under review.

Fisher & Paykel Healthcare Corporation Ltd (ASX:FPH) closed at A$38.89 on 05 November 2026, gaining 4.32% during the session. The S&P/ASX 200 (XJO) rose 2.61%, adding 230.60 points to close at 9,065.10, while the S&P/ASX 200 Health Care index (XHJ) advanced 3.64%, up 1,240.30 points to 35,329.10. Overnight Wall Street gains, driven by the Democrats' decisive victory in the U.S. midterm elections, provided a tailwind for global Equity markets. Fisher & Paykel Healthcare is a leading designer, manufacturer, and marketer of products and systems for respiratory care, surgery, and the treatment of obstructive sleep apnea, with sales across more than 120 countries.

Land Sale Agreement with Health New Zealand

On 5 October 2026, Fisher & Paykel Healthcare announced it had entered into an agreement to sell 13 hectares of its 105-hectare site on Karaka Road in Drury, New Zealand, to Health New Zealand for a purchase price of NZ$45.3 million. Health NZ intends to use the land to develop a future hospital facility to serve the growing South Auckland population. The site is located next to the future Ngākōroa train station and is fronted by State Highway 22, providing transport connectivity.

New Zealand Health Minister Simeon Brown described the Acquisition as a significant Investment in long-term healthcare infrastructure for one of the country's fastest-growing regions. The government has asked National Infrastructure Funding and Financing (NIFCO) to lead the delivery work alongside Health NZ.

Retained Land and Campus Development Plans

Fisher & Paykel Healthcare will retain the remaining land on the Karaka Road site for the development of its planned second campus in New Zealand. The company's rezoning application for the site is currently under review by Auckland Council. The company originally purchased the 105-hectare site in September 2022, with two scheduled instalment payments completed and a final payment of NZ$15 million due in December 2026.

Managing Director and CEO Lewis Gradon noted that locating a major new hospital alongside a world-class Research and Development campus creates a foundation for innovation in medical technologies. Settlement of the sale to Health NZ is expected between March and June 2027, subject to certain sale and purchase conditions. The impact will be reported as an abnormal item, with existing full-year Earnings guidance unchanged.

About the Company

Fisher & Paykel Healthcare is dual-listed on the NZX and ASX and is headquartered in Auckland, New Zealand. The company specialises in designing and Manufacturing medical devices for respiratory care, including hospital and homecare products for breathing support. Its products are used in acute and chronic respiratory care, surgery, and the treatment of obstructive sleep apnea across more than 120 countries worldwide.

Sector Context

The Australian healthcare sector saw broad-based gains on 05 November 2026, with the S&P/ASX 200 Health Care index adding 3.64%. Fisher & Paykel Healthcare's 4.32% gain outperformed the sector benchmark. The company's dual-country presence in New Zealand and Australia, combined with its global sales network, positions it within both the medical device and healthcare infrastructure themes that attracted investor attention during the session.

Risks

Risks for Fisher & Paykel Healthcare include potential delays in the Auckland Council rezoning process for its Drury campus development. The land sale settlement is subject to conditions that could affect timing. Foreign exchange movements, particularly in the NZD/AUD and NZD/USD pairs, impact reported earnings. Competition in the respiratory care device market and changes to hospital procurement practices in key markets represent ongoing operational risks.

Catalysts on Watch

The settlement of the land sale between March and June 2027 will generate cash proceeds and could support future Capital allocation decisions. Progress on the Auckland Council rezoning application for the remaining Drury site will determine the timeline for the company's second New Zealand campus. First-half FY2027 results, against previously issued guidance, will provide visibility on the company's operational trajectory.

The Bottom Line

Fisher & Paykel Healthcare's agreement to sell a portion of its Drury land to Health New Zealand for NZ$45.3 million represents a transaction that monetises surplus land while retaining the bulk of the site for its own campus development. The co-location of a hospital alongside a research and development precinct could offer long-term collaboration opportunities, while the near-term focus remains on settlement and rezoning progress.

FAQs

Q: How much land is Fisher & Paykel Healthcare selling and for what price?

A: The company is selling 13 hectares of its 105-hectare Drury site to Health New Zealand for NZ$45.3 million.

Q: What will the land be used for?

A: Health New Zealand intends to develop a future hospital facility to serve South Auckland's growing population.

Q: When is the land sale expected to settle?

A: Settlement is expected between March and June 2027, subject to certain sale and purchase conditions.

Q: What will Fisher & Paykel Healthcare do with the remaining land?

A: The company retains the remaining land for its planned second New Zealand campus, with a rezoning application under review by Auckland Council.

Q: How did FPH shares perform on 05 November 2026?

A: Fisher & Paykel Healthcare shares closed at A$38.89, up 4.32%, outperforming the S&P/ASX 200 Health Care index gain of 3.64%.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.